Pricing Sign in

QNRX

Quoin Pharmaceuticalsdistress 8/10 · high distress / dilution risk

$4.25-3%today-81% from 52w high

quoinpharma.com4 employeesFounded 2018Ashburn, VABiotechnology

Lead: Netherton Syndrome

Revenue

pre-revenue

Liquidity

$14M

Runway

0.9 yrs

Shares 1y

+2692%

Price & events

-56.0% over 6M

CatalystRating changeDilutionFinancingdashed = today

-2.9%

1D

+2.2%

1W

+30.8%

1M

-25.8%

3M

-55.7%

6M

-49.4%

1Y

-80.3%

2Y

-100.0%

5Y

-100.0%

All

Overview

Market Cap: $14.26B
Volume: 1.91K
52 Week Range: $3.25 – $22.30
Total Shares: 3.35B
Float Shares: 1.63M
Short %: 13.09%
% Held by Insiders: 2.63%
% Held by Institutions: 52.50%
RVOL: 0.00x
Beta: 1.66

Pipeline stages · 1 programs

QRX003

Preclin›

Ph1›

Ph2›

Ph3›

Filed›

PDUFA›

Approved

next 2026-07-30

Pipeline · 4 trials · 2 upcoming

Readout	Phase	Drug	Indication	Enroll	Status
2026-07-30 Estimated 50% readout ~2026-10-13	Phase 2/3	QRX003, 4% Lotionrare pediatricorphanfast track	Netherton Syndrome	—	recruiting
2027-01-31 Estimated 50% readout ~2027-04-16	Phase 2/3	QRX003rare pediatricorphanfast track	Netherton Syndrome	—	recruiting
2025-12-30	Phase 2/3	QRX003, 4% Lotionrare pediatricorphanfast track	Netherton Syndrome	20	recruiting
2025-12-30	Phase 2/3	QRX003-2% Lotion, QRX003-4% Lotion QAM, Vehicle, QRX003-4% Lotion BIDrare pediatricorphanfast track	Netherton Syndrome	30	active not recruiting

Catalyst news & presentations · 10

2027Guided 40%regulatory submissionFiled (NDA/BLA)QRX003 · Potential NDA filingSEC 8-K
late 2026/early 2027Guided 70%regulatory submissionFiled (NDA/BLA)QRX003 · NDA submission in US and other territoriesSEC 8-K
second half of 2026Guided 55%readoutPhase 3QRX003 · Top-line data from pivotal trialsSEC 8-K
later in the yearGuided 40%regulatory submissionFiled (NDA/BLA)QRX003 · NDA submission plannedSEC 8-K
second half of 2026Guided 55%trial initiationsecondaryPhase 3QRX003 · Initiate pivotal Phase 3 studySEC 8-K
first half of 2026trial initiationsecondaryrapamycin topical formulations · commence clinical testingSEC 8-K
first half of 2026enrollment completesecondaryPhase 3QRX003 · Enrollment completion in two pivotal trialsSEC 8-K
2026-06-23fda agreementQRX003 · FDA conditionally approved QYLEKI as proposed brand name for QRX003.SEC 8-K
end of Q1 2026enrollment completesecondaryPhase 3QRX003 · Completion of recruitment into both pivotal studies CL-QRX003-002 and CL-QRX003-003.SEC 8-K
2025-05-22fda agreementQRX003 · FDA clearance to initiate second pivotal Netherton Syndrome clinical study CL-QRX003-002.SEC 8-K

Approved drugs (0)

none — clinical-stage

Capital structure — dilution & financing

Shares out: 3,354,650,799 · 2 offerings/1y · 1 PIPEs

2026-06-02424B3offering
2025-12-05424B3offering
2025-12-04EFFECTshelf_effective
2025-11-07S-3shelf_registration
2025-10-158-Kprivate_placement
2025-04-03EFFECTshelf_effective
2024-12-268-Kmaterial_agreement

🔒 Positioning — Pro

Short interest / days-to-cover, insider buys & sells.

🔒 Top holders — Pro

Institutional ownership + quarter-over-quarter accumulation/trimming.

Wall St ratings

strong buy · target $21 (+404% upside) · 5 analysts

2026-05-04LUCID CAPITAL MARKETSBuy

Competitors — Netherton Syndrome

AZTRAzitra, Inc.$2M · D7

Recent news

Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.